EV3 NEUROVASCULAR

What the Data Shows About EV3 NEUROVASCULAR

EV3 NEUROVASCULAR is associated with 3,790 adverse-event reports in the FDA Manufacturer and User Facility Device Experience (MAUDE) database , spanning reports dated from 2006 through 2016. Of the total, 277 are coded as death reports and 2,080 as injury reports, with the remainder classified as malfunctions or other event types. These counts reflect reports submitted to the FDA by manufacturers, healthcare facilities, and patients — they are raw signal, not adjudicated safety findings, and higher-volume manufacturers or older product portfolios naturally generate larger raw counts.

The reports span 14 distinct device types attributed to this manufacturer in MAUDE, which means any safety read for EV3 NEUROVASCULAR should be reviewed at the device-family level rather than company-wide. Across those devices, 4 distinct event types appear in the record, led by Injury at 2,080 reports (54.9% of total). Patient-outcome categorizations are reported across 12 distinct outcomes, giving a shaped distribution rather than a single headline figure.

Year-over-year reporting volume is tracked across 10 years of MAUDE data, with the peak single-year volume reaching 1,017 reports — trend shape can reflect shifts in device sales, FDA reporting requirements, or post-market recall activity as much as intrinsic device performance. The MAUDE system is one input among many in FDA post-market surveillance and does not draw safety conclusions from individual submissions. All figures reflect the openFDA snapshot refreshed on 2026-05-15, and nothing on this page is medical or regulatory advice — consult a qualified clinician or the FDA for current safety communications.